UK tribunal upholds CMA pharma collusion fine

The UK’s Competition Appeal Tribunal has confirmed the Competition and Markets Authority’s finding that Lexon colluded with rival drug suppliers to keep up prices of an antidepressant sold to the National Health Service.


Get unlimited access to all Global Competition Review content